无锡药明康德新药开发股份有限公司 group: subsidiaries and structure
企业 · 无锡市, China · LEI 254900OEPQLZSPLN9175
2subsidiaries
1countries
0held directly
1lapsed LEIs
1links on accounts older than 24 months
0ISINs of subsidiaries
Summary
无锡药明康德新药开发股份有限公司 is the ultimate parent of 2 subsidiaries with LEIs in 1 country, as reported to GLEIF. 0 are held directly; the others sit below intermediate companies. All of them are in Hong Kong. 1 of the subsidiaries has a lapsed LEI, and 1 link rests on accounts older than 24 months.
Written from GLEIF data using fixed, reviewed sentence templates.
Subsidiaries by country
Data-quality notes (AssetCensus analysis)
No group-level data-quality notes in this data release.
1 subsidiaries have data-quality notes; they are listed on each company page.
Group structure
Indentation shows the direct parent reported to GLEIF.
合全药业香港有限公司 Hong Kong
Subsidiaries
| Company | Country | City | LEI | Accounts year | Notes |
|---|---|---|---|---|---|
| STA PHARMACEUTICAL HONG KONG INVESTMENT LIMITED | Hong Kong | KOWLOON | 213800N7HZJ1E5B4UP89 | 2023 | lapsed > 24 months |
| 合全药业香港有限公司 | Hong Kong | 香港 | 3003004LQA2QUYTZAT54 | 2025 |